Perioperative Support Center, Saiseikai Yokohamashi Tobu Hospital, 3-6-1 Shimo-Sueyoshi, Tsurumi-Ku, Yokohama, Kanagawa, 230-8765, Japan.
Department of Anesthesiology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Kanagawa, Japan.
J Anesth. 2020 Aug;34(4):502-511. doi: 10.1007/s00540-020-02777-9. Epub 2020 Apr 17.
The aim of this study was to assess the effect of scheduled intravenous acetaminophen (SIVA) on the incidence of postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic gynecologic surgery (LGS).
This retrospective observational study identified consecutive patients who underwent LGS at our institution from January to November of 2017 and were managed with either our hospital's old protocol (Group H) or a new protocol using SIVA (Group S). Primary outcomes included the incidences of PONV and the amount of additional antiemetic required in the postoperative period. The secondary outcomes included the pain score on postoperative day 1, the requirement for additional analgesic medications, and the length of hospitalization (LOH).
Patients in Group S had significantly lower incidences of PONV from postoperative days 0 to 1 and required significantly less antiemetics or tramadol than those in Group H (P = 0.0085). Patients at a low risk for PONV in Group S had significantly lower incidences of PONV than those in Group H (P = 0.0129). Further, the amount of additional tramadol required was lower in Group S than in Group H (P = 0.0021).
Introduction of SIVA into the postoperative pain management protocol of LGS may reduce the incidence of PONV and the amount of adjunctive antiemetic medication required from postoperative days 0 to 1. In patients undergoing LGS, PONV prophylaxis using antiemetics should be prescribed depending on PONV risk profile; however, SIVA prophylaxis can be used in all patients regardless of PONV risk profile.
本研究旨在评估计划性静脉给予对乙酰氨基酚(SIVA)对行腹腔镜妇科手术(LGS)患者术后恶心呕吐(PONV)发生率的影响。
本回顾性观察性研究纳入了 2017 年 1 月至 11 月在我院行 LGS 的连续患者,他们分别接受我院旧方案(H 组)或新方案(S 组,使用 SIVA)治疗。主要结局包括 PONV 的发生率和术后期间需要额外止吐药的量。次要结局包括术后第 1 天的疼痛评分、需要额外镇痛药物的情况以及住院时间(LOH)。
S 组患者从术后第 0 天到第 1 天 PONV 的发生率显著降低,并且需要的止吐药或曲马多明显少于 H 组(P = 0.0085)。S 组低 PONV 风险患者的 PONV 发生率明显低于 H 组(P = 0.0129)。此外,S 组需要额外曲马多的量也低于 H 组(P = 0.0021)。
在 LGS 的术后疼痛管理方案中引入 SIVA 可能会降低术后第 0 天至第 1 天 PONV 的发生率和所需的辅助止吐药的量。在接受 LGS 的患者中,应根据 PONV 风险状况来开预防性止吐药;但是,无论 PONV 风险状况如何,都可以使用 SIVA 预防。